Background. Enteroviruses are shed in human stool and can cause a wide spectrum of illness. They are the leading cause of aseptic meningitis.
Enteroviruses (EVs) cause 10-15 million symptomatic infections in the United States annually [1] , and EV infection can be acquired through ingestion of infectious fecal material and oral or respiratory secretions [2, 3] . Transmission is more frequent in places where Historically, virus isolation has been used to diagnose EV infection, usually through fecal, respiratory, or CSF specimen inoculation into cell cultures (primary or continuous cell lines) or suckling mice. Isolates are identified using serotype-specific neutralizing antibodies [5] . Unfortunately, viral culture is slow and labor intensive and usually cannot produce a result within a clinically relevant time. Furthermore, certain EV serotypes replicate poorly, if at all, in commonly used cell lines, and use of suckling mice in clinical diagnostics has decreased sharply in recent years. More recently, clinical laboratories have adopted nucleic acid amplification techniques (e.g., RT-PCR), using primers targeted to highly conserved EV genome regions [6] . These methods are highly specific and sensitive and can detect virus directly in clinical specimens. Molecular methods are also now widely used for EV typing; RT-PCR amplifies a portion of the genome's capsid-coding region (usually the region encoding major viral capsid protein 1 [VP1]), and the PCR product sequence is compared with reference sequences of known serotypes [7] .
Although risk of poliomyelitis among nonimmunized travelers to tropical, developing countries is well documented [8] , other travel-related EV disease has not been frequently reported, perhaps because of low clinical attack rates and nonspecific symptoms. We report an investigation of an outbreak of nonpolio EV disease among travelers to Mexico that included use of novel laboratory detection methods for the determination of etiologic outcome.
On 30 June 2004, the director of the Yale-New Haven Hospital Clinical Virology Laboratory contacted the Connecticut Department of Public Health to notify of 2 high school students hospitalized with confirmed EV meningitis after a schoolorganized religious trip to Mexico that involved 29 travelers. The Connecticut Department of Public Health conducted an investigation to determine the extent of the outbreak, to implement immediate infection-control measures, and to improve understanding of such outbreaks to aid in future prevention efforts.
METHODS
To identify potentially related illnesses outside the 29 trip participants, we contacted the youth organization that organized the school's trip, notified the Centers for Disease Control and Prevention (CDC), and posted a case inquiry on Epi-X, the CDC's national epidemic information exchange for public health officials.
All trip participants were interviewed regarding religious mission-related and recreational activities, food and drink exposures, hygienic practices during the 10 days of their trip, and any symptoms of illness during their trip or 2 weeks after returning from the trip. We obtained menu lists for all meals; all meals were eaten as a group. Travelers were requested to provide stool specimens, which underwent culture for EV at the Connecticut Department of Public Health (Hartford) and were tested by EV-specific nucleic acid sequence-based amplification (NASBA) at Yale-New Haven Hospital (New Haven, CT) and by EV VP1 seminested RT-PCR (RT-snPCR) at the CDC (Atlanta, GA). Available CSF specimens ( ) collected n p 4 for treatment purposes were forwarded to the CDC for VP1 RT-snPCR.
Stool culture. A stool-coated sterile swab was added to 1 mL of inoculation minimal essential media containing 2% fetal bovine serum; the tube was vortexed for 10 s. Then, 0.1 mL of the resulting stool suspension was added to each cell culture tube (cell lines were primary monkey kidney, normal human fibroblast, and A549); these tubes were placed on a rocker platform at 33ЊC for у1 h. An additional 1 mL of inoculation minimal essential media was added to all tubes before incubation at 33ЊC in humidified 5% carbon dioxide atmosphere. Tubes were inspected daily. When typical EV cytopathic effect was observed, cells were tested by indirect immunofluorescence with EV group-specific monoclonal antibodies. EV-positive isolates were serotyped using indirect immunofluorescence with monoclonal antibodies specific for individual EV serotypes (Millipore).
NASBA. NucliSens basic kit (bioMérieux) was used for EV RNA extraction and detection in accordance with the manufacturer's EV NASBA protocol [9] . RNA was isolated from 100 mL (stool) or 200 mL (CSF) of specimen with use of a modified Boom method [10] with Nuclisens kit reagents. BioMérieux's EV-specific internal control (i.e., cloned EV sequences containing a 20-bp potato-leaf-roll virus fragment) was added to each specimen to evaluate RNA extraction and amplification efficiency. EV amplification products were detected by hybridization in 2 separate reactions using 2 different probes, 1 of which was specific for the EV product and 1 of which was specific for internal control product; both contained generic ruthenium-labeled electrochemiluminescence detection probe.
EV VP1 RT-snPCR. EV VP1-specific RT-PCR and sequencing were conducted as described elsewhere [11] . Fecal specimens were pretreated by extraction of a 10% suspension with 0.1 mL chloroform, followed by extraction with 1 mL Vertrel XF (Miller-Stephenson Chemical). RNA was extracted from clinical specimens, fecal extracts, and virus isolates with use of the QIAamp Viral RNA Mini Kit (Qiagen).
cDNA was synthesized with use of primers in the VP1 capsid protein-encoding genome region. PCR was performed using degenerate, inosine-containing primers in the genome region encoding VP3 and VP1 capsid proteins, to produce an ∼700-base pair first-round product. One microliter of the first PCR product was added to a second PCR containing degenerate primers (both within VP1), resulting in a 320-350-base pair product. Reaction products were separated and visualized on agarose gel and were purified using QIAquick Gel Extraction Kit (Qiagen). Resulting DNA templates were sequenced with the same primers with use of Big Dye Terminator, version 1.1, Ready Reaction Cycle Sequencing Kit on an ABI Prism 3100 automated sequencer (Applied Biosystems).
Amplicon sequences were compared with VP1 sequences of EV reference strains, including у1 representative of each recognized serotype, by script-driven sequential pairwise comparison, using Gap (Wisconsin Sequence Analysis Package, version 10.3; Accelrys), as described elsewhere [12] [13] [14] . A partial VP1 nucleotide sequence identity of 175% confirmed the serotype in the specimen.
Data analysis. Travelers with EV identified by culture, NASBA, or PCR in any specimen were considered to have EV infection. Travelers with a specimen available and no evidence of EV infection by laboratory testing were considered to not have EV infection. Symptoms were not used to classify travelers as infected or uninfected because of the wide illness spectrum that can result from EV infection, including asymptomatic infections and the possibility of other similar concurrent travelrelated illnesses.
An epicurve was constructed by plotting acute illnesses among travelers with onset during the trip or 2 weeks after the group's return. Epicurve boxes were marked with laboratory results for each ill traveler and their symptom group. Two symptom groups were developed-a group with headache and/ or vomiting and a group with diarrhea but not headache or vomiting-to separate those with symptoms potentially consistent with traveler's diarrhea from those with symptoms more consistent with viral meningitis (i.e., headache and/or vomiting).
To report the symptomatology of the 2 predominant EV infections (i.e., echovirus [E] 30 and coxsackievirus [CV] A1), we calculated the frequencies of symptoms in the groups of patients stratified by laboratory results (i.e., all patients infected with E30, patients infected with only E30, all patients infected with CVA1, patients infected with only CVA1, and patients who had no EV detected). The groups of all patients infected with E30 and all patients infected with CVA1 were used to create larger comparison groups to increase statistical power. Fisher's exact test was used to identify statistically significant associations between symptoms and outcomes for patients infected with specific EVs, compared with control subjects who did not have EV detected.
For analysis of risk factors, 3 travelers with illness onset after 27 June were excluded, because they likely contracted infection from other ill trip members (i.e., these illnesses were secondary cases); this determination was based on delayed symptom timing after the primary illness peak (figure 1). Because of excluded cases, analysis of risk factors was conducted as a nested casecontrol study rather than as a cohort study. Univariate ORs for EV infection were calculated for all exposures. Because of small numbers, Fisher's exact test was used to test for statistical significance of dichotomous variables, the Mann-Whitney 2-sample statistic was used for continuous variables, and Cuzick's nonparametric test for trend across ordered groups was used for trend testing. This outbreak investigation underwent human subjects review at the CDC and was determined to be public health practice rather than research activity (HSR #2004-00293).
RESULTS

Outbreak time course.
Of the 29 travelers (25 teenagers and 4 adult chaperones), 21 (72%) became ill. An epicurve (figure 1) with all illnesses depicted by onset date shows a sharp peak in onset of illness; most illnesses occurred within 3 days after return to the United States. A small, presumably secondary illness peak occurred 4 days after the primary peak. Of the 21 ill travelers, 14 (67%) had headache or vomiting and 7 (33%) had diarrhea but not headache or vomiting ( figure 1) .
Laboratory results. Twenty-seven travelers (including 20 of the 21 ill travelers) provided stool samples (figure 2). E30 was yielded by culture in 5 stool specimens; no other EVs were identified by culture. EV was identified in the same 18 stool samples by both NASBA and VP1 RT-snPCR. CVA1 was identified in 15 samples, and E30 was identified in 3 samples. Only 1 EV was identified in each stool sample by VP1 RT-snPCR; this method usually identifies only the most abundant EV in the sample and not necessarily all EVs present. Among 5 stool samples that were culture positive for E30, VP1 RT-snPCR identified CVA1 in 4 and E30 in 1. Among 4 CSF samples obtained, VP1 RT-snPCR identified E30 in 3 and CVA5 in 1. One E30-positive CSF samples was from an ill traveler who did not have a stool sample obtained. Overall, on the basis of all of the testing performed for 28 travelers, 4 travelers had only E30 identified, 11 had only CVA1 identified, 4 had both E30 and CVA1 identified, 1 had CVA5 identified, and 8 had no EV identified (figure 2).
The mean duration from onset of illness to sample collection was similar for NASBA-and PCR-negative samples and NASBA-and PCR-positive samples (10 and 11 days, respectively;
, by Mann-Whitney comparison of means). P p .332
Bacterial stool cultures were performed for the 7 travelers who had diarrhea only (figure 1). One culture yielded Salmonella enterica serotype Kentucky; the results of the other cultures were negative.
Symptoms. The frequencies of symptoms stratified by the travelers' results of testing for EV (excluding the traveler who had only CVA5 identified) are presented in table 1. Headache, nausea, vomiting, and subjective fever were the most frequent symptoms among the 8 travelers with E30 infection and were significantly more frequent among this group than among the EV-negative travelers. Among 11 travelers who had only CVA1 identified, diarrhea and nausea were the most frequent symptoms (frequency for both, 36%). Five infected travelers (all infected with CVA1 only) were not ill, and thus, data for them are not shown in figure 1 , which plots travelers according to the date of illness onset.
Risk factors for infection. Activities significantly associated with EV infection were playing soccer with villagers during the afternoon of arrival in the fishing village (OR, 12.5; 95% CI, 1.2-168.8) and swimming in the Gulf of Mexico during a trip to a nearby island (OR for each additional hour spent swimming that day, 14.3; 95% CI, 1.3-154.3). The soccer game occurred 7 days before the primary illness peak; the swimming occurred 4 days before this peak. Because no increase in the risk of infection was found with increased time spent playing soccer and because the timing of the sea swim exposure matched the incubation period estimated for our secondary (20) 3 (27) 1 (14) Conjunctival infection
NOTE. Presence of echovirus (E) 30 or coxsackievirus (CV) A1 was determined by stool culture, stool PCR, or CSF PCR. Of the 28 travelers who had their specimens tested for enterovirus, 2 were excluded from this analysis (1 of whom did not have a clinical specimen obtained, and 1 of whom had CVA5 identified in a CSF sample and had no evidence of E30 or CVA1 infection).
a Excludes travelers with evidence of coinfection with other enteroviruses, although more travelers may have been coinfected, because species-specific PCR only identifies the most abundant enterovirus species present. b Symptoms that were statistically significantly more frequent ( , by Fisher's exact test) among travelers with enterovirus P ! .05 infection outcome (E30 or CVA1) than among travelers who had no enterovirus detected.
cases (i.e., the 4 days between illness peaks), we considered sea swimming to be the likely source of the outbreak and focused additional analysis on this. Despite extensive analysis of individual menu items, meals, and drinks, no food or drink exposures were associated with increased risk of infection. Seventeen (59%) of the 29 travelers reported always using hand sanitizer before meals; hand sanitizer use before meals was not associated with lower risk of EV infection. Table 2 shows associations between EV infection and seawater exposure during the travelers' swim on 21 June 2004. ORs under "All travelers" are for associations between seawater exposure and EV infection, comparing EV-positive patients with EV-negative control subjects; 3 patients with secondary cases were excluded from this comparison. Only 3 travelers did not swim, but 2 of these travelers, including the only infected patient who did not swim, visited the beach with other travelers. All sea swimming exposures were associated with increased risk of EV infection, but only the time spent swimming was significantly associated with increased risk of EV infection, as noted previously.
Both EV-negative control subjects who swallowed seawater had diarrheal illnesses with onset during the primary illness peak. Table 2 also shows an analysis of associations between infection and seawater exposure, with the exclusion of ill EVnegative travelers from the control group (i.e., EV-positive patients vs. well EV-negative control subjects). All associations had higher estimates for risk of seawater exposure than those calculated when ill control subjects were included. A statistically significant trend toward increased risk of EV infection was observed for swallowing seawater (OR, 16.0), compared with swimming without recalling any swallowing of water (OR, 12.0) and with not swimming at all (OR, 1.0 [reference]; , P p .040 by Cuzick's nonparametric trend test)
DISCUSSION
We report an outbreak of primarily EV illnesses associated with youth-group travel to Mexico. Illness onset dates were tightly clustered, consistent with point-source exposure. Laboratory testing identified multiple pathogens (E30, CVA1, CVA5, and S. Kentucky), all of which were shed in infected human feces. Analysis of exposures suggests that a sea swim 4 days before the primary illness peak was the infection source, likely because of sewage-contaminated seawater. To our knowledge, this is the first reported outbreak of EV infection associated with seawater swimming. Furthermore, this is only the second reported out- break in which CVA1 infection was confirmed, requiring novel laboratory methodologies for identification (although whether CVA1 caused illness is unclear). The high morbidity observed among these travelers was likely because of E30 infection. Asymptomatic and mild infections are reportedly representative of most EV infections [1] . However, published reports [15, 16] documented high rates of symptomatic disease in other outbreaks of E30 infection. Two investigations of child-care center-associated outbreaks of E30 infection found that 52%-59% of adults with serologically confirmed E30 infection were symptomatic and that 18%-21% had meningitis [15, 16] . In accordance with the known predisposition of E30 to cause more cases of aseptic meningitis than do other EVs [17] , we found that only meningitis-associated symptoms (i.e., headache, fever, vomiting, and nausea) were significantly associated with E30 infection. We did not identify any asymptomatic E30 infections.
In contrast, it is ambiguous whether CVA1 infection caused any illness. The only prior documented CVA1-associated outbreak was an outbreak of diarrhea among immunocompromised children who had recently undergone bone marrow transplantations [18, 19] . CVA1 was also identified in a single student traveler to Mexico who had low-grade fever, chills, nausea, and diarrhea in a small study that investigated the viral etiologies of traveler's diarrhea [20] . Similarly, the most frequent symptoms in our investigation among those who had only CVA1 identified were nausea and diarrhea (frequency for each, 36%); however, neither symptom was significantly associated with CVA1 infection, and 5 patients were asymptomatic. However, small numbers likely limited our ability to identify significant associations with specific symptoms. Notably, CVA1 was not found in any CSF sample, suggesting that CVA1 likely was not a cause of viral meningitis in this cohort.
Historically, CVA1 has had a wide geographic distribution [21] , but only 9 cases of CVA1 infection have been reported to the National Enterovirus Surveillance System since the establishment of the voluntary passive system in 1970 [22] . CVA1 grows poorly in cell culture, and isolation generally requires inoculation of suckling mice [23, 24] . Currently, suckling mice are infrequently used for viral diagnostics; thus, few clinical laboratories can detect CVA1. Until this outbreak, the CDC identified CVA1 only 6 times since 1962 (last in 1982), always by suckling-mouse inoculation.
The new, ultrasensitive VP1 RT-snPCR assay allows detection and identification of noncultivable EVs without sucklingmouse inoculation [11] . The EV genome was detected with equivalent sensitivity with use of NASBA at Yale-New Haven Hospital's Clinical Virology Laboratory. EV genus-specific NASBA and RT-PCR are increasingly available in clinical laboratories, allowing greater sensitivity in detecting EV. Illustratively, only 5 of 18 NASBA-positive samples were viral culture positive. However, the genome region targeted by genus-specific molecular assays commonly used in clinical laboratories cannot differentiate serotypes [7] .
The steep primary illness peak indicates a point-source exposure. The secondary illness peak occurred 4 days after the first, indicating a 4-day incubation period (which is within the usual 3-6-day incubation period for EV [2] ). Four days before the primary illness peak, the group participated in a prolonged sea swim. All seawater exposures were associated with increased risk of EV infection; time spent swimming was significantly associated with infection. CVA1 and E30, as well as S. Kentucky and the other pathogens, were likely present in the same fecescontaminated seawater, resulting in this outbreak of mixed infection.
We removed travelers with diarrheal illnesses from the control group, because such illnesses might have been caused by infections due to other undetected pathogens for which we did not test (i.e., other enteric viruses) that resulted from the same exposure (i.e., sewage-contaminated seawater). Including patients with such illnesses in the control group might have hindered the identification of risk factors for illness. Removing patients with these illnesses from the control group increased point estimates for all seawater exposure associations, supporting our hypothesis that sea swimming caused this outbreak. Furthermore, a significant trend in increasing risk of infection was observed for swallowing seawater, compared with swimming without swallowing water and with not swimming.
Although outbreaks of EV infection resulting from sea swimming have not been reported previously, other contaminated natural waters have been implicated in other outbreaks of EV infection [25, 26] ; inadequately chlorinated contaminated swimming pools have also been implicated [27] [28] [29] . E30-contaminated river water and groundwater sources were implicated in a drinking water-associated outbreak of E30 infection [30] , illustrating the ability of E30 to remain viable in natural waters. In addition, other viral infections resulting from seawater exposure have been documented in multiple studies [31, 32] .
During this outbreak, seawater may have become contaminated from raw sewage disposal relatively near shore, resulting in observed EV illness and other enteric illnesses after sea swimming. Environmental agencies have been concerned about sewage treatment and disposal practices in the Gulf of Mexico [33] , particularly in Mexico's Quintana Roo state [34] , which was this group's destination. Travelers should be aware of risks associated with swimming in natural waters when visiting areas with limited sewage treatment. Travelers should avoid swimming in oceans and lakes (1) near urban areas where sewage might be inadequately treated; (2) after heavy rainfalls, which may overwhelm sewage systems, causing increased natural-water contamination; and (3) near water outflows (i.e., pipes or rivers), because such outflows can bring contaminated water into swimming areas [35] .
The primary limitation of our investigation is the small number of travelers in the group; this likely affected our ability to identify statistically significant associations and precluded multivariate analysis. Furthermore, all but 3 travelers swam in the seawater; this limited our power to identify statistically significant associations between seawater exposure and EV infection. Finally, we were unable to test the seawater for EV because of the site's distance and because of the time elapsed between exposure and recognition of the probable exposure source. We also did not test stool samples from travelers for other viral agents that may have caused diarrheal symptoms.
In summary, we report high morbidity associated with an outbreak of EV disease among travelers to Mexico that likely occurred as a result of swimming in sewage-contaminated seawater. Travelers and physicians who advise them should be aware of health risks associated with global recreational water use and of ways to reduce risk. Finally, EV VP1 RT-snPCR is a new methodology that will likely assist in real-time etiologic outcome assessment of future outbreaks of EV infection.
